CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
Cladribinedrug
Likely dose
Cladribine 3.5 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03933215
NCT03933215N/ACompleted
CompareCT.gov

Cladribine Tablets: Observational Evaluation of Effectiveness and PROs in Suboptimally Controlled Patients Previously Taking Injectable DMDs for RMS (CLICK-MS)

EMD Serono Research & Development Institute, Inc.·observational·Posted May 1, 2019·Updated Apr 29, 2025

In Brief

An observational study evaluating Cladribine for Multiple Sclerosis. Completed, enrolled 100 participants across 18 sites.

Detailed Summary

To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS),who transition to cladribine tablets after suboptimal response to any injectable disease-modifying drugs (DMDs) approved in the United States (US) for RMS in a real-world setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsMerck KGaA, Darmstadt, Germany

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 1, 2019
Enrollment StartMay 21, 2019
Primary CompletionMar 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.2 years ago

Interventions

Cladribinedrug

Participants received cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.